# A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease

> **NCT05015127** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Harbour BioMed (Guangzhou) Co. Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Thyroid Ophthalmopathy

## Interventions

- **DRUG:** HBM9161 680 mg qw by q2w from week 13
- **DRUG:** Placebo
- **DRUG:** HBM9161 680 mg qw by q2w from week 7
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05015127
- **Lead sponsor:** Harbour BioMed (Guangzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-22
- **Primary completion:** 2022-10
- **Final completion:** 2022-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2022-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05015127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05015127, "A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05015127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*